Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
Hear from expert rheumatologist Dr James Galloway about the updated regulatory guidance on JAK inhibitors.
Learn more about the role of Xeljanz (tofacitinib citrate) in the treatment of RA, using real world evidence to support efficacy and safety data.
Find out more about the progression and management of RA from an expert clinician, where Dr Cole gives a review of current treatments and therapies in the management of the disease.
Find a range of articles and training support on our inflammation therapy area on PfizerPro.
Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024